Women in Psychedelics: Building a More Inclusive Industry
January 27th, 2021
Psychedelics, Top News
The psychedelics industry has become one of the fastest-growing markets in the world as promising research highlights its potential to treat conditions ranging from depression to eating disorders, chronic pain, PTSD, fibromyalgia and beyond. With the FDA onboard, several psychedelics companies have successfully raised capital and are in the process of completing clinical trials designed to bring these therapeutics to market.
Women have played a key—and often underappreciated—role in the industry’s development. While they were intimately involved in counseling sessions, recruitment and other key areas, they were very rarely identified in published work since the 1950s. The psychedelic renaissance has created an opportunity for women to take the reigns in the industry’s rebirth in the 2020s.
Women Taking Senior Roles
The #CanndoraConnect: Women in Psychedelics conference on December 2, 2020 brought together eight leading women in the industry to share their expertise on critical psychedelic topics, including the science behind psilocybin and its role in women’s health. The panelists included women holding titles ranging from senior executives to research scientists.
“To me, using plant-based psychedelics for mental health is the best gift we could have been given by nature to improve the predicament we have found ourselves in by relying on non-plant based medicines, such as opioids and narcotics,” said Anne Barnes, Director of Red Light Holland, and participant in the December conference.
Barnes was drawn to the psychedelics industry by her passion for plant-based health solutions. With a background in corporate law, business and public speaking, she founded Peace Naturals, the first company to receive a license to produce medical cannabis in 2013. She has since become Director for Red Light Holland, which is focused on the production and distribution of magic truffles in the Netherlands.
The complete list of panelists included:
- Ann Barnes, Director of Red Light Holland
- Sarah Hashkes, CEO of Radix Motion
- Terri Smith, Chief Mycologist of WAKE & CEO of WAKE Jamaica
- Dr. Olga Chernoloz, Chief Scientific Officer of WAKE
- Susan Chapelle, President of Havn Life
- Irie Selkirk, Co-founder & Director of Rise Wellness Retreats
- Salimeh Tabrizi, Co-Founder Canadian Psychedelic Association
- Sabrina Ramkellawan: COO & Co-Founder Knowde Group Inc. & President Clinical Research Association of Canada
Of course, these women aren’t the only women that are playing a key role in the psychedelics industry. Dr. Jillian Hagel is Chief Technology Officer of MagicMed Industries Inc. (CSE: MGIC reserved), which is focused on developing and patenting psychedelic derivative molecules that it plans on licensing out to third parties to develop into approved therapeutics.
Diversity Improves Research & Outcomes
The psychedelics industry is keen to avoid some of the diversity issues affecting the cannabis industry—another business that made the jump from illicit to licit in recent times.
The cannabis industry has been widely criticized for its exclusion of women and minorities. Despite the disproportionate level of cannabis enforcement against minorities in the past, minority-owned businesses have struggled to participate in the legal industry’s upside. Gender equality has been another challenge facing the industry as it evolves.
In addition to overcoming these challenges, the psychedelics industry has also struggled with limited female-focused research. Studies examining women independent from men are scarce even though meta-analyses suggest that women experience more intense effects than men—possibly due to the susceptibility of the serotonin-releasing effects of some drugs.
“Psychedelics can directly help women deal with mental health issues to become more empowered,” says Ann Barnes. “Reviewing mental health history and how women have been treated and diagnosed in the last 100 years, medical treatments have been very much to the detriment of women.
“Their symptoms have been whisked away as previously a woman’s mental pain was ‘justin in their mind’ or worse, dealt with using opioids and narcotics to numb the issue. Currently, with the massive amount of research being done by the psychedelics community, I believe that psychedelics will be an imperative part of women’s health.”
The psychedelics industry would be wise to keep in mind that gender equality is correlated with a higher return on equity and average earnings. In addition, the inclusion of women-focused psychedelics studies helps everyone by better understanding the nuances of psychedelics and how they affect potential patient populations.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.